NYSE · SOLV

Solventum Corporation

$78.01 +$0.77 (+1.00%) 1D After hours
Charting by TradingView

Key Metrics

$13.38B
Market cap
9.34×
P/E · TTM
$8.26B
Revenue · TTM
$1.43B
Net income
EPS · TTM $8.19
Dividend yield —
Free cash flow −$203.00M
Beta · 1Y 0.71
EBITDA · TTM $2.19B
Gross margin 53.7%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 20
    A material event was filed (Form 8-K).

    8-K - Solventum Corp (0001964738) (Filer)

    RECEIPT: SEC FORM 8-K, TIMESTAMPED
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$13.38B
Enterprise value$17.90B
Shares outstanding173.2M
52-wk range$62.38 – $88.20
Avg volume · 20D1.3M
Net cash −$4.52B
Book value / share$28.43
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNYSE
About Solventum Corporation
IPO dateMar 26, 2024
Employees20000

Solventum Corp is a healthcare company developing, manufacturing, and commercializing solutions leveraging material science, data science, and digital capabilities to address customer and patient needs. Its segments include MedSurg, which earns maximum revenue and provides wound therapy, I.V.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E9.34
P/S1.62
P/FCF—
EV/EBITDA8.19
EV/Sales2.17
Graham №$72.39

Profitability

Gross 53.7%
Operating 20.5%
Net 17.3%
FCF -2.5%
ROE / ROIC 36.1% · 15.1%

Financial Health

Current ratio1.07
Quick ratio0.75
Debt / equity1.02
Debt / EBITDA 2.32
Net cash −$4.52B
Working capital$237.00M

Cash Flow · TTM

Operating CF $151.00M
Capex −$354.00M
Free cash flow −$203.00M
Buybacks —
Dividends paid —
Shareholder yield —

Piotroski F-Score

6 / 9
Middling fundamentals · 6 of 9 signals passing

Altman Z-Score

2.1
Grey zone (1.81–2.99) · monitor

Graham Number vs Price

$72.39 vs $78.01
Trades 1.1× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings